Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

Tas, Faruk; Derin, Duygu; Guney, Pınar; Aydiner, Adnan; Topuz, Erkan

doi:10.1007/s10147-007-0757-8

Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

Copy For Citation

Tas F., Derin D., Guney N., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded)

Publication Type: Article / Article
Volume: 13 Issue: 4
Publication Date: 2008
Doi Number: 10.1007/s10147-007-0757-8
Journal Name: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.330-334
Istanbul University Affiliated: Yes

Abstract

Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.